AARD
NASDAQ
$3.97
Aardvark Therapeutics Inc (AARD)
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company is headquartered in San Diego, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $15.44 (+288.92%)
Market Cap
$87M
Free Cash Flow Yield
-70.94%
Beta (5Y)
1.61
Price Chart
Valuation
Market Cap$87M
P/B1.03
Profitability
EBITDA-$75M
EPS-$3.21
Financial Health
Free Cash Flow Yield-70.94%
Growth & Risk
Beta (5Y)1.61
Sharpe Ratio-0.26